Biologically effective dose distribution based on the linear quadratic model and its clinical relevance

Lee, Steve P.; Leu, Min Y.; Smathers, James B.; McBride, William H.; Parker, Robert G.; Withers, H. Rodney

doi:10.1016/0360-3016(95)00162-r

Cited by 117 publications

(61 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A second process that might slightly reduce the a/b estimate when large fractions are used is the increased effect of dose inhomogeneity on dose intensity as fraction size increases, so-called 'triple trouble' [23]. Dose inhomogeneity ('double trouble') is always bad, and is important even when 2.0 Gy fractions are used [24,25]. Simple calculations show that the added impact of hypofractionation (triple trouble) can be ignored for practical purposes provided full dose compensation is applied.…”

Section: Discussionmentioning

confidence: 99%

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

Agrawal¹,

Alhasso²,

Barrett-Lee³

et al. 2011

Radiotherapy and Oncology

215

View full text Add to dashboard Cite

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

show abstract

Section: Discussionmentioning

confidence: 99%

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

Agrawal¹,

Alhasso²,

Barrett-Lee³

et al. 2011

Radiotherapy and Oncology

215

View full text Add to dashboard Cite

show abstract

“…10 In addition, radiotherapy techniques have greatly improved, leading to more homogeneous dose distributions and therefore to a lower chance of toxicity. 53 Partial shielding of the heart 10 was applied in our cohort, depending on tumor localization. We could not examine possible dose-effect or dose-volume relations because details on radiation dose and volume were not collected.…”

Section: Org Frommentioning

confidence: 99%

Late cardiotoxicity after treatment for Hodgkin lymphoma

Aleman

Belt-Dusebout

Bruin

et al. 2006

Blood

644

438

View full text Add to dashboard Cite

We assessed cardiovascular disease (CVD) incidence in 1474 survivors of Hodgkin lymphoma (HL) younger than 41 years at treatment . Multivariable Cox regression and competing risk analyses were used to quantify treatment effects on CVD risk. After a median follow-up of 18.7 years, risks of myocardial infarction (MI) and congestive heart failure (CHF) were strongly increased compared with the general population (standardized incidence ratios [SIRs] ‫؍‬ 3.6 and 4.9, respectively), resulting in 35.7 excess cases of MI and 25.6 excess cases of CHF per 10 000 patients/year. SIRs of all CVDs combined remained increased for at least 25 years and were more strongly elevated in younger patients. Mediastinal radiotherapy significantly increased the risks of MI, angina pectoris, CHF, and valvular disorders (2-to 7-fold). Anthracyclines significantly added to the elevated risks of CHF and valvular disorders from mediastinal RT (hazard ratios [HRs] were 2.81 and 2.10, respectively). The 25-year cumulative incidence of CHF after mediastinal radiotherapy and anthracyclines in competing risk analyses was 7.9%. In conclu IntroductionOver the past decades, survival of patients treated for Hodgkin lymphoma (HL) has improved dramatically, as a result of the development of multiagent chemotherapy (CT), more accurate radiotherapy (RT), and enhanced possibilities to reduce treatment complications. 1 Unfortunately, the improved prognosis of HL has been accompanied by long-term toxicity, such as elevated risks of second primary malignancies, 2-9 cardiovascular disease (CVD), 2,3,[8][9][10] and infections. 2,8,9 Increased mortality of cardiac disease after mediastinal radiotherapy for HL has been reported in several studies. 2,3,[8][9][10] Dose-dependent anthracycline-induced cardiotoxicity has been observed in survivors of malignancies other than HL, who were usually treated with higher anthracycline doses. 11,12 It is not known, therefore, whether anthracyclines add to the increased risk of CVD from mediastinal RT for survivors of HL. This is an important clinical question because most patients with HL now receive anthracycline-containing chemotherapy. Although a few studies reported on nonfatal cardiac events, comparisons with the general population were usually not made, because in most countries CVD incidence rates are not available. [13][14][15][16][17][18] The purpose of our study was to assess the long-term risk of various CVDs in a cohort of 1474 five-year survivors of HL treated between 1965 and 1995.Unique features of this study include long and near complete follow-up and the availability of complete treatment data, including radiation fields and chemotherapeutic agents. In addition, we compared the incidence of various CVDs with population-based reference rates from the general population, we accounted for competing risk of death from any cause, and we incorporated cardiac risk factors in the analyses. Patients and methods Data collection proceduresWe included all 5-year survivors of HL diagnosed before age 41 years (n ϭ 148...

show abstract

“…For example, Lee et al [27] recently supplemented external beam isodose distributions with two dimensional iso-biological effective dose contours after accounting for tissue radiosensitivity and treatment fraction schedules. Although the present knowledge of the important radioresponse parameters may be limited, biological considerations, relative to the standard physics calculations (such as Medical Internal Radiation Dosimetry, MIRD, which compute average dose and can ignore dose heterogeneity), may more reliably predict radiation treatment outcomes in animal studies involving radiation dose heterogeneity.…”

Section: Discussionmentioning

confidence: 99%

CT-simulator based brachytherapy planner:Seed localization and incorporation of biological considerations

Mayer

Fong

Frankel

et al. 1998

Radiat. Oncol. Investig.

View full text Add to dashboard Cite

Biologically effective dose distribution based on the linear quadratic model and its clinical relevance

Cited by 117 publications

References 34 publications

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

Late cardiotoxicity after treatment for Hodgkin lymphoma

CT-simulator based brachytherapy planner:Seed localization and incorporation of biological considerations

Contact Info

Product

Resources

About